Suzuken Co Ltd (JP:9987)
:9987
Want to see JP:9987 full AI Analyst Report?
Top Page
Suzuken Co
(9987)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥5,546.00
▼(-12.48% Downside)
Action:Upgraded
Date:05/15/26
The score is driven primarily by strong financial fundamentals (especially the very low-leverage balance sheet and improving profitability) and an attractive valuation (low P/E with a dividend). These positives are partly offset by very weak technicals, with the stock trading well below key moving averages and negative momentum indicators despite oversold readings.
Positive Factors
Very conservative balance sheet
Near-zero debt and a large, stable equity base materially reduce financial risk, preserving flexibility to invest in logistics, absorb shocks, and sustain operations. This durable low-leverage profile supports long-term resilience and strategic optionality.
Negative Factors
Volatile cash generation
Large year-to-year swings in operating and free cash flow indicate working-capital sensitivity and inconsistent cash conversion. This reduces predictability for capex, dividends, and M&A, increasing execution risk for multi-quarter strategic plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Very conservative balance sheet
Near-zero debt and a large, stable equity base materially reduce financial risk, preserving flexibility to invest in logistics, absorb shocks, and sustain operations. This durable low-leverage profile supports long-term resilience and strategic optionality.
Read all positive factors
Suzuken Co (9987) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥301.20B
Dividend Yield1.6%
Average Volume (3M)163.97K
Price to Earnings (P/E)10.9
Beta (1Y)0.43
Revenue Growth3.61%
EPS Growth20.83%
CountryJP
Employees13,086
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)440.22
Shares Outstanding72,167,206
10 Day Avg. Volume143,650
30 Day Avg. Volume163,966
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)1.00
Price to Sales (P/S)0.17
P/FCF Ratio22.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥7,100.00Price Target Upside12.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)398.18
Revenue Forecast (FY)¥2.55T
Suzuken Co Business Overview & Revenue Model
Company Description
Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Busine...
How the Company Makes Money
Suzuken makes money mainly through wholesale distribution of pharmaceuticals and other healthcare-related products. Its core revenue stream is the sale of prescription medicines and related items to customers such as hospitals, clinics, and dispen...
Suzuken Co Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.41T | 2.49T | 2.40T | 2.39T | 2.31T | 2.24T |
| Gross Profit | 192.18B | 192.53B | 192.23B | 185.25B | 179.69B | 167.33B |
| EBITDA | 49.55B | 48.72B | 49.19B | 43.62B | 41.45B | 30.14B |
| Net Income | 33.32B | 38.14B | 34.50B | 29.02B | 20.34B | 14.39B |
Balance Sheet | ||||||
| Total Assets | 1.15T | 1.16T | 1.11T | 1.23T | 1.15T | 1.14T |
| Cash, Cash Equivalents and Short-Term Investments | 142.20B | 141.67B | 141.58B | 242.11B | 192.70B | 201.46B |
| Total Debt | 23.85B | 0.00 | 1.80B | 1.80B | 1.80B | 1.88B |
| Total Liabilities | 744.12B | 739.75B | 706.41B | 812.26B | 734.57B | 723.65B |
| Stockholders Equity | 402.16B | 415.88B | 407.29B | 416.31B | 411.21B | 417.69B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 18.50B | -79.39B | 76.41B | 22.21B | -1.64B |
| Operating Cash Flow | 0.00 | 33.57B | -65.08B | 87.22B | 37.27B | 9.52B |
| Investing Cash Flow | 0.00 | 12.82B | 20.38B | 10.35B | -46.36B | 1.44B |
| Financing Cash Flow | 0.00 | -33.34B | -35.48B | -31.72B | -26.22B | -11.60B |
Suzuken Co Technical Analysis
Negative
6337.00
Price Trends
5820.41
Negative
6041.10
Negative
5923.02
Negative
Market Momentum
-179.92
Positive
42.20
Neutral
67.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9987, the sentiment is Negative. The current price of 6337 is above the 20-day moving average (MA) of 5526.00, above the 50-day MA of 5820.41, and above the 200-day MA of 5923.02, indicating a bearish trend. The MACD of -179.92 indicates Positive momentum. The RSI at 42.20 is Neutral, neither overbought nor oversold. The STOCH value of 67.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9987.
Suzuken Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥301.20B | 10.88 | 8.60% | 1.60% | 3.61% | 20.83% | |
69 Neutral | ¥514.12B | 14.22 | 6.39% | 2.27% | 3.98% | 7.00% | |
68 Neutral | ¥435.07B | 14.57 | 11.37% | 3.04% | 5.08% | 2.07% | |
67 Neutral | ¥358.08B | 16.82 | ― | 0.41% | 14.59% | 7.84% | |
66 Neutral | ¥423.73B | 11.01 | 6.92% | 2.69% | 4.83% | 56.24% | |
66 Neutral | ¥563.64B | 17.44 | 15.71% | 0.96% | 15.07% | 72.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:9987
Suzuken Co
5,306.00
193.59
3.79%
JP:2784
Alfresa Holdings
2,220.50
356.13
19.10%
JP:7459
Medipal Holdings
2,834.00
638.43
29.08%
JP:9989
Sundrug Co
3,721.00
-652.42
-14.92%
JP:7649
Sugi Holdings Co
2,990.50
-40.50
-1.34%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,745.00
423.78
12.76%
Suzuken Co Corporate Events
Suzuken Boosts Shareholder Returns With Higher Dividend and New Payout Policy
May 14, 2026
Suzuken has approved a new shareholder return policy that targets a total payout ratio of 100 percent through a combination of dividends and flexible share repurchases, while adopting dividend on equity as a key performance indicator to stabilize ...
Suzuken to Implement Two-for-One Stock Split to Broaden Investor Base
May 14, 2026
Suzuken’s board has approved a two-for-one stock split of its common shares, effective October 1, 2026, with September 30, 2026 set as the record date. The move will double the number of shares outstanding to 144,334,408, while leaving autho...
Suzuken Unveils Medium-Term Plan to Build Next-Generation Pharmaceutical Distribution Model
May 14, 2026
Suzuken has unveiled a three-year Medium-Term Management Plan running from the fiscal year ending March 2027 to March 2029, positioning it as a key execution phase toward achieving a sustainable 8% return on equity by the fiscal year ending March ...
Suzuken lifts profit and maintains dividend as it prepares stock split and softer earnings outlook
May 14, 2026
Suzuken reported consolidated net sales of ¥2.49 trillion for the year ended March 31, 2026, up 3.6% year on year, while operating profit slipped 2.0% to ¥36.4 billion but ordinary profit rose 2.4% and profit attributable to owners of pa...
Suzuken Completes ¥26 Billion Share Buyback Program
Mar 9, 2026
Suzuken has completed a share repurchase program authorized in May 2025, underscoring continued efforts to optimize its capital structure and enhance shareholder returns. In the latest tranche conducted from March 2 to March 6, 2026, the company b...
Suzuken Nears Completion of ¥26 Billion Share Buyback Program
Mar 2, 2026
Suzuken has provided an update on its ongoing share repurchase program, disclosing that it bought back 375,900 common shares in February 2026 for a total of approximately 2.41 billion yen through market purchases on the Tokyo Stock Exchange. This ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.